Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis.

Trial Profile

Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Zoledronic acid (Primary) ; Docetaxel
  • Indications Cancer metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2015 Status changed from recruiting to completed as per the record of University Hospital Medical Information Network - Japan.
    • 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 01 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top